Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 28, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
On October 27, 2005, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 59,732 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The Company was advised of these transactions on October 28, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
Key Facts for Investor Verification
- Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in shares held within the GSK Trust in the same capacity as other employees.
- The specific transaction involved the transfer of 59,732 Ordinary Shares to employee plan participants.
- The report was signed by Victoria Llewellyn as the Authorised Signatory on October 28, 2005.